A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

Launched by EASTERN HEPATOBILIARY SURGERY HOSPITAL · Jan 8, 2009

Keywords

ClinConnect Summary

Hepatocellular carcinoma (HCC) represents a major health care challenge in the present era, with its incidence rate of 71128 cases and the mortality rate of 679871 cases during 2007 in the world. Although liver transplantation, resection and locally ablative therapies remain useful treatment preference in patients with early HCC, but they often cannot be availed because of either disease progression or outgrowth of treatment criteria, especially for liver resection. Moreover, after resection, recurrence of liver tumor can be expected in as many as 70% of patients within 5 years which leadin...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues
• • 2. Karnofsky Performance Score performance over 60
• • 3. The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy.
• • 4. The liver function is of grade A or B in Child-Pugh classification.
• • 5. Patients give consent to the test.
• Exclusion Criteria:
• • 1. Negative expression of HAb18G/CD147 in the HCC tissues
• • 2. Allergic history to biologic products(Licartin)
• • 3. Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l.
• • 4. Severed disease of the heart, lung, kidney, brain and blood system.
• • 5. Other severed disease might affect the trial .
• • 6. Patients would not sign the consent to the trial.